A successful cardiac transplantation program using combined university and community resources

Area of Science:

• Cardiology
• Transplantation Medicine
• Immunosuppression Therapy

Background:

• End-stage heart disease and cardiac failure significantly impact patient prognosis.
• Orthotopic cardiac transplantation offers a potential solution for patients with end-stage heart disease.

Purpose of the Study:

• To evaluate the efficacy and outcomes of orthotopic cardiac transplantation in patients with end-stage heart disease.
• To assess the impact of immunosuppressive regimens, including cyclosporine, on transplant success and patient recovery.

Main Methods:

• Retrospective analysis of 75 patients with end-stage heart disease evaluated between August 1984 and August 1986.
• Twenty-five patients underwent orthotopic cardiac transplantation with short ischemic times (<4 hours).
• Immunosuppression initially involved cyclosporine and prednisone, with azathioprine added to reduce steroid dosage. Rejection episodes were treated with methylprednisolone, antithymocyte globulin, or OKT3.

Main Results:

• Seventeen of 25 transplanted patients (68%) survived 3-24 months post-transplant.
• All patients experienced rejection; 13 had severe episodes (average 3.1/patient).
• Survivors showed significant functional improvement, with 17 of 18 in NYHA Class I and 15 returning to full activity or employment.

Conclusions:

• Orthotopic cardiac transplantation, supported by advancements in patient care and immunosuppression (cyclosporine), is an effective treatment for end-stage heart disease.
• Despite challenges with rejection and infection, the procedure can restore significant functional capacity and improve quality of life.